^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + azenosertib (ZN-c3) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
N-c3, a potent and selective Wee-1 inhibitor demonstrates anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance
Published date:
03/09/2022
Excerpt:
In the ER-positive MCF-7 efficacy model, ZN-c3 demonstrated anti-tumor activity as a single agent as well as in combinations with a CDK4/6 inhibitor (Palbociclib) or ZN-c5, a selective estrogen receptor degrader (SERD)...In summary, these results demonstrate that ZN-c3 is effective as a single agent and in combination with other targeted therapies in breast cancer models...ZN-c3 is currently in clinical trials for several indications and has demonstrated promising clinical activity and good tolerability.
